Indeed, loss of this myeloid cell subset upon GM-CSF blockade correlated with a significant decrease in tumor growth (Supplementary Fig. 7j), underscoring this treatment as a potential therapeutic approach in NrasG12D/PtenKO HCC. Here, CSF2 is linked to neoplasm.